Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | HCK | P08631 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482833 | 0.89 | NR1H2 (0.43) | NR1H2MAPTALDH1A1SMN1; SMN2BRD4 | |
| SCHEMBL1455275 | 0.84 | HTR6 (0.47) | FGFR1HSP90AA1HSP90AB1PIK3CDABL1 | |
| SCHEMBL832377 | 0.84 | GABRG2 (0.44) | SMN1; SMN2FGFR1RIPK1RIPK3HTR6 | |
| SCHEMBL24569520 | 0.84 | ALDH1A1 (0.37) | NR1H2MAPTALDH1A1SMN1; SMN2FGFR1 | |
| SCHEMBL29888720 | 0.84 | ALDH1A1 (0.37) | NR1H2MAPTALDH1A1SMN1; SMN2FGFR1 | |
| SCHEMBL559567 | 0.83 | SIK1 (0.44) | SMN1; SMN2HSP90AA1HSP90AB1PIK3CARIPK1 | |
| SCHEMBL4819554 | 0.83 | GABRG2 (0.49) | MAPTALDH1A1SMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL30847454 | 0.83 | SIK1 (0.44) | SMN1; SMN2HSP90AA1HSP90AB1PIK3CARIPK1 | |
| SCHEMBL6174196 | 0.82 | HCAR3 (0.53) | ALDH1A1HSD17B10FGFR1RIPK1RIPK3 | |
| SCHEMBL34467402 | 0.82 | FGFR1 (0.51) | MAPTALDH1A1FGFR1RIPK1RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
| CN-111315738-B | Inhibitors of glutaminyl cyclase | 维沃永治疗股份公司 | 2021-08-03 | — | — | CN | disclosed |
| US-20200223825-A1 | INHIBITORS OF GLUTAMINYL CYCLASE | VIVORYON THERAPEUTICS N.V (DE) | 2020-07-16 | — | — | US | disclosed |
| CN-111315738-A | Inhibitors of glutaminyl cyclase | 维沃永治疗股份公司 | 2020-06-19 | — | — | CN | disclosed |
| EP-3461819-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3461819-A1 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2019-04-03 | — | — | EP | disclosed |
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | NR1H2 4511/4885MAPT 3971/4885ALDH1A1 3717/4885 |
| US-20200223825-A1 | INHIBITORS OF GLUTAMINYL CYCLASE | QPCT, QPCTL, GLUL | NR1H2 4375/4885MAPT 459/4885ALDH1A1 2670/4885 |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | NR1H2 704/4885MAPT 4702/4885ALDH1A1 360/4885 |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | NR1H2 4375/4885MAPT 459/4885ALDH1A1 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.